{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-004119","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2026-06-15T12:00:25+00:00","discovered_at":"2026-06-15T12:05:16.426500+00:00","generated_at":"2026-06-15T12:07:47.899005+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aptose TUSCANY trial shows 86.2% CRc in newly diagnosed AML; all TP53-mut respond","bullets":["Composite complete response (CRc) rate 86.2% in evaluable patients across all TUS+VEN+AZA dose groups.","MRD negativity rate 86.4% in patients achieving CR/CRh; 62.5% overall MRD negative among all dosed.","160mg cohort: 100% CR in 4 TP53-mutated patients with complex karyotype; 76.9% CRc across 13 patients.","No treatment-related deaths, QT prolongation, CPK elevations, or differentiation syndrome observed.","19 patients remain on treatment; 6 proceeded to stem cell transplantation."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-004119","json":"https://secwatch.observer/filing/0001171843-26-004119.json","markdown":"https://secwatch.observer/filing/0001171843-26-004119.md","text":"https://secwatch.observer/filing/0001171843-26-004119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184326004119/0001171843-26-004119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184326004119/f8k_061326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:07:47.899005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}